Login
$AARD
$1.21 -$0.05 (4.22%) After hours

$AARD SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 8-K: Results of Operations and Financial Condition

FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS)

13 Nov 2026 10-Q
10 Nov 2026 Form 4: Lee Tien-Li, Director

Granted 793,951 Stock Option (right to buy) · Disposed of 793,951 Stock Option (right to buy) (Disposition to Issuer)

10 Nov 2026 Form 4: Sun Nelson, See Remarks

Granted 304,094 Stock Option (right to buy) · Disposed of 304,094 Stock Option (right to buy) (Disposition to Issuer)

10 Nov 2026 Form 4: Jaiman Manasi, Chief Medical Officer

Granted 374,560 Stock Option (right to buy) · Disposed of 374,560 Stock Option (right to buy) (Disposition to Issuer)

23 Oct 2026 8-K: Other Events

Disclaimer Aardvark Therapeutics, Inc. (“we”, “us,” “our” or the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and n...

22 Oct 2026 8-K: Other Events

Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

08 Oct 2026 Form 4: Zhang Zhongwei, Director

Granted 127,061 Stock Option (right to buy)

08 Oct 2026 Form 3: Zhang Zhongwei, Director

No securities owned

08 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche

11 Sep 2026 Form 4: Sun Nelson, See Remarks

Sold 14,754 shares ($73.8K) · Sold 62,000 shares ($321K)

11 Sep 2026 144
10 Sep 2026 144
21 Aug 2026 Form 4: Chi Jeffrey, Director

Granted 44,964 Stock Option (right to buy)

21 Aug 2026 Form 4: Graf Susan E, Director

Granted 44,964 Stock Option (right to buy)

21 Aug 2026 Form 4: Baynes Roy D., Director

Granted 44,964 Stock Option (right to buy)

21 Aug 2026 Form 4: Tong Victor Edward Jr, Director

Granted 44,964 Stock Option (right to buy)

17 Aug 2026 8-K: Submission of Matters to a Vote of Security Holders

On August 14, 2026, Aardvark Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 21,884,158 shares of the Company’s common stock outstanding as of June 18, 2026, the record date ...

11 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support